Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Editas Competitor CRISPR Therapeutics Hails European Patent Decision

CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.

Intellectual Property Companies

UK-US Trans-Atlantic Precision Collaborations Target Pancreatic Cancer

A goal of "Precision Panc" in the UK and US-based "Precision Promise" is to create a knowledge bank of integrated data for the development of bespoke personalized treatments for pancreatic cancer patients.

Clinical Trials Analysis

UK BioPharma Players Told 'Think Global, Act Local' For Post-Brexit World

The multi-faceted UK life sciences industry has been told to develop more connective tissue and encourage a more activist government industrial strategy to help it thrive after the country departs the European Union.

Brexit United Kingdom

UK Orphan Drug Access Slammed; Shire Calls For Urgent 'Access Summit'

Orphan drugs "are falling through the cracks" of the UK’s market access process, Shire's country general manager tells the Pink Sheet and calls for urgent all-party remedial talks.

Health Technology Assessment Rare Diseases

With Promising Data, Janssen To Ready Vaccine For Next Ebola Outbreak

J&J says it will work with regulators to position its investigational Ebola Zaire vaccine for use in future outbreaks after publishing impressive Phase I prophylactic data in healthy volunteers.

Commercial Rare Diseases

Is Anemic Growth Sending Novo Nordisk After Global Blood Therapeutics?

Once high-flying Novo Nordisk has been sending out M&A signals as it seeks a solution to weak growth, so analysts aren't surprised to see the Danish diabetes giant stalking US-based Global Blood Therapeutics.

M & A Business Strategies
See All